The recent surge in capital into specialized pharmaceutical companies, particularly those focusing on groundbreaking therapies and complex drug development programs, has fueled what some are calling "High Roller Pharma." While the potential for revolutionary treatments and significant returns is certain, the connected risks are also notable. Many o